Exciting Updates from SNO 2024: Berubicin Study Shows Promise in GBM Treatment At the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024), CNS Pharmaceuticals, Inc. unveiled the latest data from their groundbreaking study on Berubicin, a novel anthracycline being investigated for the treatment of glioblastoma (GBM). The primary analysis data presented at the…

Exciting News for Melcor Real Estate Investment Trust and Melcor Developments Ltd. Amended Agreement with Improved Consideration EDMONTON, Alberta, Nov. 25, 2024 (GLOBE NEWSWIRE) — Melcor Real Estate Investment Trust (“Melcor REIT” or the “REIT”) (TSX: MR.UN) and Melcor Developments Ltd. (“Melcor” or the “Purchaser”) (TSX: MRD) are pleased to announce that they have entered…

Nvidia’s Revenue Growth Slows, Impact on Stock Price Predictable Revenue Patterns and Investor Sentiment Nvidia, a leading technology company known for its graphics processing units (GPUs), has been experiencing a slowdown in its revenue growth rate. This has raised concerns among investors, as the company’s current valuation already reflects high expectations for future performance. Nvidia’s…

The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Evolv Technologies Holdings, Inc. Investor Alert LOS ANGELES, CA / ACCESSWIRE / November 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Evolv Technologies Holdings, Inc. (“Evolv” or “the Company”) (NASDAQ:EVLV) for…

Charmingly Eccentric: A Look Inside the Humacyte Class Action Lawsuit Investor Alert: The Schall Law Firm Reminds Investors of Deadline in the Humacyte Class Action Lawsuit LOS ANGELES, CA / ACCESSWIRE / November 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, has issued a reminder to investors regarding a class…